A-shares closed · 港股休市 Quotes 行情 · 25 Sep 17:19 CST
27 Sep 2026 · 20:05 CST Terminal Access 终端入口 →
600196.SH上海证券交易所 · 主板 Main

Fosun Pharma 复星医药

Chemical Pharmaceuticals 化学制药
¥22.84−¥0.29 · −1.25%Delayed 行情延迟 · 24 Sep 2026 · 16:14 CST · CNY
Open 开盘
¥23.10
High 最高
¥23.23
Low 最低
¥22.80
Prev Close 昨收
¥23.13
Volume 成交量
1,593.7万股
Turnover 成交额
¥3.66亿
Mkt Cap 总市值
¥610亿
P/E 市盈率
18.0×
Recent Activity 近期动态All Filings 全部公告 →

17 significant filings since 30 May 2026: 2 on share pledge, 5 on guarantee or financial assistance and 4 on pledge released, and 4 other kinds. The latest, on 24 Sep 2026: 复星医药关于控股子公司签订合作与许可协议的公告.
自 30 May 2026 起有 17 份重大公告:share pledge 2 份、guarantee or financial assistance 5 份、pledge released 4 份,另有 4 类。最新一份(24 Sep 2026):复星医药关于控股子公司签订合作与许可协议的公告。

Price History 价格走势

1,250 trading days 个交易日 · High 最高 ¥81.70 · Low 最低 ¥20.35
30.0040.0050.0060.0070.0080.00
Volume 成交量
1.31亿
20212022202420252026

Against Its Own History 与自身历史比较

18.0×
Median 中值 24.0× · Range 区间 17.6× to 35.5× · 20 periods 期
1.25×
Median 中值 1.61× · Range 区间 1.23× to 3.57× · 20 periods 期

Period by Period 逐期

Period 报告期Close at Period End 期末收盘TTM EPS 滚动每股收益 BPS 每股净资产
30 Jun 2026 中报¥22.47¥1.2817.6×¥18.251.23×
31 Mar 2026 一季报¥26.63¥1.3120.3×¥18.401.45×
31 Dec 2025 年报¥26.49¥1.2720.9×¥18.251.45×
30 Sep 2025 三季报¥29.84¥1.2424.1×¥17.991.66×
30 Jun 2025 中报¥25.09¥1.2220.6×¥17.751.41×
31 Mar 2025 一季报¥24.83¥1.1022.6×¥17.941.38×
31 Dec 2024 年报¥24.85¥1.0423.9×¥17.691.40×
30 Sep 2024 三季报¥27.67¥0.7835.5×¥17.711.56×
30 Jun 2024 中报¥22.14¥0.6832.6×¥17.571.26×
31 Mar 2024 一季报¥23.07¥0.7530.8×¥17.341.33×
31 Dec 2023 年报¥25.03¥0.8928.1×¥17.101.46×
30 Sep 2023 三季报¥28.60¥1.3521.2×¥17.181.66×
30 Jun 2023 中报¥30.90¥1.5020.6×¥17.011.82×
31 Mar 2023 一季报¥32.39¥1.6220.0×¥16.991.91×
31 Dec 2022 年报¥35.24¥1.4324.6×¥16.682.11×
30 Sep 2022 三季报¥29.56¥1.4021.1×¥16.301.81×
30 Jun 2022 中报¥44.09¥1.4829.8×¥14.902.96×
31 Mar 2022 一季报¥53.33¥1.7031.4×¥14.963.57×
31 Dec 2021 年报¥48.94¥1.8526.5×¥15.293.20×
30 Sep 2021 三季报¥52.30¥1.8528.3×¥15.193.44×

Consensus Forward EPS 机构预测每股收益

No broker forecasts for this company yet 暂无机构预测

Not Computed 未计算
  • Dividend Yield 股息率
  • Free Cash Flow 自由现金流
  • EV/EBITDA